Nivolumab-induced diabetes mellitus—a case report with literature review of the treatment options
BackgroundImmune checkpoint inhibitor (ICI) treatment has become important for treating various cancer types, including metastatic renal cell carcinoma. However, ICI treatment can lead to endocrine immune-related adverse events (irAEs) by overstimulating the patient’s immune system. Here, we report...
Main Authors: | Eveline Daetwyler, Alfred Zippelius, Simona Danioth, Marc Y. Donath, Lara Gut |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1248919/full |
Similar Items
-
Challenges and Limitations of Endocrine Toxicity Evaluation in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy—Retrospective Study from a Tertiary-Level Hospital in Romania
by: Simona Coniac, et al.
Published: (2023-05-01) -
Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments
by: Xueyan Wang, et al.
Published: (2022-10-01) -
Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment
by: Sridha Ganesh, et al.
Published: (2022-09-01) -
Rapidly progressing dyspnea and retiform purpura
by: Bianca Y. Kang, MD, et al.
Published: (2022-12-01) -
Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis
by: Hiroyuki Ando, et al.
Published: (2021-10-01)